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The 3rd International Workshop on Insulin & Cancer was held on October 30-31, 2010 at the German Cancer
Research Centre in Heidelberg/Germany. The topics followed-up the discussions of the previous workshops: possi-
ble differences in mitogenicity between natural insulin and genetically engineered insulin derivatives (insulin analo-
gues), as shown by laboratory studies and epidemiologic studies alike; molecular studies on the links between
metabolic and mitogenic effects of insulin, and of hyperinsulinaemia in particular; epidemiologic evidence of inter-
ferences between insulin and other hormones, particularly sex hormones, and obesity-associated cancer; the invol-
vement of inflammatory cytokines produced by fat tissue in obesity-associated cancer; aspects of drug-design
(binding drugs to albumin) and, last but not least, detection and investigation of circulating cancer cells.
Report
Since the previous International Workshops on Insulin
and Cancer held in Düsseldorf/Germany in 2007 and in
2008 [1], considerable progress in the study of the issue
has been noticeable. Hence, the 3rd International Work-
shop moved to the German Cancer Research Centre in
Heidelberg/Germany, attracting 15 speakers and an
audience of 40 participants from many countries. Like
the previous ones, the 3
rd workshop was sponsored
entirely by private persons and non-profit organisations,
namely the Insulin Dependent Diabetes Trust (IDDT)
from Northampton/UK, the Förderverein für Kinder
und Jugendliche mit Diabetes mellitus der Universität
Köln from Cologne/Germany, and the German Cancer
Research Centre (DKFZ).
The sessions started with issues related to the mito-
genicity of insulin analogues. With respect to the recent
commission by the EMEA “to further investigate the
possible increased risk of cancer associated with the use
of insulin glargine...” [2], the safety profile of insulin
glargine (Lantus®) was of particular interest. Kristin
Eckardt reviewed the most recent laboratory studies on
this topic, including previous own data. Doris Mayer
presented her recent investigations of insulin analogues
in breast cancer cells showing an increased mitogenicity
of Lantus® in cells highly expressing IGF-1 receptors.
Haim Werner showed his studies on differences in sig-
nalling between long-acting insulin analogues (insulin
glargine [Lantus®] or insulin detemir [Levemir®]) which
may be contributing to an increased mitogenicity of
these compounds. Together with results from other
experimental studies and epidemiological data published
recently, these findings seem to underpin the safety con-
cerns, which in May 2010 had led the EMEA to with-
hold unlimited approval of Lantus® (“.... the Marketing
Authorization Holder should submit one additional
renewal application in 5 years time”) [2]. Harald
Enzmann, representative of the German regulatory
board BfArM and co-author of several cell culture stu-
dies on Lantus®, presented the regulator’sp e r s p e c t i v eo f
insulin analogues. He considered the safety record for
Lantus® “inconclusive”. A commentary from the floor
cautioned that Lantus® in vivo undergoes biotransforma-
tion into lesser mitogenic compounds. This process,
however, exhibits considerable inter-individual variabil-
ity. Thus, subjects with a slow biotransformation and,
consequently, a longer incubation time with Lantus®
in vivo, may be at increased risk for development and
progression of malignancies [3]. Such an association
m a yp r o b a b l yr e m a i nu n d e t e c t a b l eb yc o n v e n t i o n a l
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cluded in a paper by Müssig et al., that “ studies are
warranted to identify and follow patients potentially at
risk for cancer because of altered insulin glargine bio-
transformation” [3].
A study from a regional cancer registry was presented
by Hans W. Hense. For the first time in Germany, the
regional diabetes treatment registry was linked with the
cancer registry, showing an increased incidence of liver
cancer, and decreased incidence of breast and prostate
cancer, in type-2 diabetic patients. However, the effects
of the type of anti-diabetic treatment have as yet not
been fully evaluated.
The next sessions dealt with basic science data. Aurelio
Teleman reported on his work on insulin signalling in
Drosophila in which he found a phosphatase subunit
(PPP2R5C) which may be a novel regulator of prolifera-
tive and metabolic effects. Boris Draznin focused on the
fact that insulin- by increasing the amount of farnesy-
lated Ras molecules- enhances the effects of growth fac-
tors such as IGF-1, and that hyperinsulinaemia thereby
augments the mitogenic effects of growth factors (e.g. on
tumour cells). Stephan Herzig alluded to chronic aber-
rant inflammatory signalling, and transcription factor
functions, involved in metabolic and mitogenic risks seen
in obese patients with type-2 diabetes mellitus. Jean
Grisouard discussed AMP-dependent kinase (AMPK)
affecting the production of adipokines (e.g. TNF alpha,
IL-6, leptin), which increase insulin resistance of adipo-
cytes, whereas Metformin activating AMPK, reduced
(pro-inflammatory) IL-6 and increased IL-1 receptor
antagonist (which is anti-inflammatory), thereby poten-
tially inhibiting IL-6 associated insulin-resistance and
IL-1 induced tumour progression. These data were lar-
gely corroborated by John Reynolds in a later session: he
found evidence for upregulated inflammatory cytokines
in the fat tissue of his patients operated for oesophageal
carcinoma.
By a kind of mirror-image, Zvi Laron reported a follow-
up of his earlier investigation on subjects with congenital
IGF-1 deficiency, observing no malignancies in more
than 500 homozygous patients, whereas various malig-
nancies were found in their heterozygous family
members.
Also Rudolf Kaaks showed a follow-up of his earlier
epidemiologic data, now focusing on the impact of insu-
lin on sex hormones and SHBG (sexual hormone bind-
ing globulin), which might explain some of the
association between obesity and cancer incidence and
proliferation.
As one of the last speakers, Eva Frei explained how
albumin can be used to transfer and accumulate drugs
or other compounds into tumour tissues; concerning
the binding of insulin detemir (Levemir®) to albumin
after subcutaneous injection, a paucity of data was
n o t e di nt h i sr e s p e c t .B u r k h a r dB r a n d tr e p o r t e do nh i s
experiences with the extraction and investigation of cir-
culating tumour cells using antibodies coupled to
nanobeads.
Taken together, considerable progress in the study of
the Insulin-Cancer-Connection was noted, making a
continuation of the International Workshops on Insulin
& Cancer desirable. Meanwhile, the proceedings of the
3
rd workshop will hopefully be published in one of
the forthcoming issues of “Diabetology & Metabolic
Syndrome” in 2011.
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